Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 95010 SAD in Healthy Males
NCT03494712Phase 1Completed
- Sponsor
- Servier
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRG-110 in heart failure (HF), sponsored by Servier. Primary endpoint: Incidence of Adverse Events at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
MRG-110
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03494712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494712.